Novartis AG ADR (NVS)vsSpace Exploration Technologies Corp. Class A Common Stock (SPCX)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
SPCX
Space Exploration Technologies Corp. Class A Common Stock
$160.95
+19.22%
INDUSTRIALS · Cap: $1.77T
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 193% more annual revenue ($56.58B vs $19.30B). NVS leads profitability with a 23.9% profit margin vs -45.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
SPCX
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for SPCX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Mega-cap, among the largest globally
15.4% revenue growth
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Trading at 27.0x book value
ROE of -11.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SPCX
The strongest argument for SPCX centers on Market Cap, Revenue Growth. Revenue growth of 15.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SPCX
The primary concerns for SPCX are EPS Growth, Price/Book, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while SPCX is a growth play — different risk/reward profiles.
SPCX is growing revenue faster at 15.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (49/100 vs 23/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Space Exploration Technologies Corp. Class A Common Stock
INDUSTRIALS · AEROSPACE & DEFENSE · USA
Space Exploration Technologies Corp. The company is headquartered in Starbase, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?